Cassava Sciences to Present at the Jefferies Global Healthcare Conference
01 Junho 2023 - 10:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced that its management has been invited to present at the
Jefferies Global Healthcare Conference in New York City.
When: |
Thursday, June 8th at 4:30 pm Eastern time |
Live Webcast: |
https://wsw.com/webcast/jeff281/sava/1846130 |
Archived Replay: |
https://www.CassavaSciences.com/company-presentations |
|
|
About SimufilamSimufilam is
Cassava Sciences’ lead product candidate. Simufilam is a
proprietary small molecule (oral) drug designed to treat and slow
the progression of Alzheimer’s disease. This drug candidate is
currently in Phase 3 clinical studies in patients with
mild-to-moderate Alzheimer’s disease dementia. Simufilam binds
tightly to an altered conformation of the filamin A protein (FLNA)
that is present in the brain of the Alzheimer’s patient and is
critical to the toxicity of Aβ42. Simufilam is wholly owned by
Cassava Sciences, without royalty or payment obligation to any
third party.
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Our novel
science is based on stabilizing—but not removing—a critical protein
in the brain. Our product candidates have not been approved by any
regulatory authority, and their safety, efficacy or other desirable
attributes have not been established in humans. For more
information, please visit: https://www.CassavaSciences.com
For More Information Contact: Eric
Schoen, Chief Financial Officer(512)
501-2450ESchoen@CassavaSciences.com
Cautionary Note Regarding
Forward-looking Statements:
Cassava Sciences periodically posts information
that may be important to investors on its website at
https://www.CassavaSciences.com. We intend to use our website as a
means of disclosing material non-public information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult Cassava Sciences’ website regularly for important
information, in addition to following Cassava Sciences’ press
releases, filings with the Securities and Exchange Commission and
public conference calls or webcasts. The information contained on,
or that may be accessed through, Cassava Sciences’ website is not
incorporated by reference into, and is not a part of, this press
release.
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024